Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 HCC detection metrics of Qliver,AFP,AFP-L3,DCP, and GALAD score

From: Discovery and validation of a novel dual-target blood test for the detection of hepatocellular carcinoma across stages from cirrhosis

Cohort

Model

Sensitivity(%)

(95%CI)

Specificity(%)

(95%CI)

PPV(%)

(95%CI)

NPV(%)

(95%CI)

Phase 1 plasma cohort

Qliver

88.68 (76.97–95.73)

[47/53]

89.34 (82.47–94.20)

[109/122]

78.33 (68.19–85.91)

[47/60]

94.78 (89.51–97.48)

[109/115]

AFP

47.17 (33.30–61.36)

[25/53]

89.34 (82.47–94.20)

[109/122]

65.79 (51.66–77.58)

[25/38]

79.56 (74.98–83.49)

[109/137]

AFPL3

41.51 (28.14–55.87)

[22/53]

86.89 (79.58–92.31)

[106/122]

57.89 (44.05–70.60)

[22/38]

77.37 (72.96–81.25)

[106/137]

DCP

62.26 (47.89–75.21)

[33/53]

85.25 (77.69–91.02)

[104/122]

64.71 (53.27–74.68)

[33/51]

83.87 (78.50–88.10)

[104/124]

GALAD

58.49 (44.13–71.86)

[31/53]

89.34 (82.47–94.20)

[109/122]

70.45 (57.62–80.70)

[31/44]

83.21 (78.16–87.28)

[109/131]

Phase 2 plasma cohort

Qliver

88.06 (77.82–94.70)

[59/67]

92.59 (84.57–97.23)

[75/81]

90.77 (81.92–95.52)

[59/65]

90.36 (82.99–94.74)

[75/83]

AFP

50.75 (38.24–63.18)

[34/67]

90.12 (81.46–95.64)

[73/81]

80.95 (67.88–89.53)

[34/42]

68.87 (63.19–74.03)

[73/106]

AFPL3

47.76 (35.40–60.33)

[32/67]

83.95 (74.12–91.17)

[68/81]

71.11 (58.50–81.13)

[32/45]

66.02 (60.26–71.34)

[68/103]

DCP

68.66 (56.16–79.44)

[46/67]

76.54 (65.82–85.25)

[62/81]

70.77 (61.27–78.74)

[46/65]

74.70 (67.00–81.11)

[62/83]

GALAD

59.70 (47.00–71.51)

[40/67]

91.36 (83.00–96.45)

[74/81]

85.11 (73.26–92.26)

[40/47]

73.27 (67.02–78.71)

[74/101]

Intended-use 10 K populationa

Qliver

88.10 (82.93–92.15)

[185/210]

92.59 (92.06–93.11)

[9065/9790]

20.33 (18.97–21.76)

[185/910]

99.72 (99.60–99.81)

[9065/9090]

AFP

50.95 (43.98–57.90)

[107/210]

90.12 (89.51–90.71)

[8823/9790]

9.96 (8.73–11.35)

[107/1074]

98.85 (98.68–98.99)

[8823/8926]

AFPL3

47.62 (40.70–54.60)

[100/210]

83.95 (83.21–84.68)

[8219/9790]

5.98 (5.20–6.88)

[100/1671]

98.68 (98.50–98.84)

[8219/8329]

DCP

68.57 (61.82–74.79)

[144/210]

76.54 (75.68–77.37)

[7493/9790]

5.90 (5.38–6.47)

[144/2441]

99.13 (98.94–99.28)

[7493/7559]

GALAD

59.52 (52.55–66.22)

[125/210]

91.36 (90.78–91.91)

[8944/9790]

12.87 (11.50–14.39)

[125/971]

99.06 (98.89–99.20)

[8944/9029]

  1. aHCC incidence is 2.1% per year in cirrhotic population according our previous study9, which is an intended-use population of Qliver
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us